This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Green Tea Extract in Treating Patients With Actinic Keratosis

This study has been terminated.
(terminated due to the low conditional power for a positive study)
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Chao Family Comprehensive Cancer Center, University of California, Irvine Identifier:
First received: April 6, 2000
Last updated: April 17, 2014
Last verified: April 2014

RATIONALE: Green tea extract contains ingredients that may inhibit the growth of actinic keratosis.

PURPOSE: Randomized phase II trial to determine the effectiveness of green tea extract in treating patients who have actinic keratosis.

Condition Intervention Phase
Non-melanomatous Skin Cancer Drug: Polyphenon E and Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Official Title: A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial of Polyphenon E Against Various Endpoints of Actinic Keratosis Pathobiology

Resource links provided by NLM:

Further study details as provided by Chao Family Comprehensive Cancer Center, University of California, Irvine:

Primary Outcome Measures:
  • Clinical and histopathologic regression of actinic keratoses [ Time Frame: 12 weeks ]

Enrollment: 88
Study Start Date: August 1999
Study Completion Date: August 2002
Primary Completion Date: August 2002 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Polyphenon E and Placebo
One arm will be assigned to be treated with topical Polyphenon E daily for 12 weeks and the other with placebo vehicle in a random, double blind manner daily for 12 weeks
Drug: Polyphenon E and Placebo
Areas of sun damaged skin with actinic keratoses to be treated will be mapped and photographed on patient's bilateral arms. One of the patient's arms will be assigned to be treated with topical Polyphenon E, the patient's other arm with placebo vehicle in a random, double blind manner. The patient's arm treatment areas will receive daily applications of a premeasured amount of drug or placebo. Patients will be seen every other week for 12 weeks to check for effects of the applications and monitor for compliance or possible side effects.
Other Name: kunecatechins ointment

Detailed Description:

OBJECTIVES: I. Determine the efficacy of the green tea extract epigallocatechin gallate (Polyphenon E topical ointment) in causing complete clinical and histopathologic regression in patients with actinic keratoses. II. Determine duration of treatment with Polyphenon E necessary to cause regression in these patients. III. Describe pathophysiologic and molecular alterations in actinic keratoses and sun damaged skin that are not present in skin that is not sun damaged in these patients. IV. Determine the effects of this treatment on biomarkers for skin cancer in these patients.

OUTLINE: This is a randomized, double blind, placebo controlled study. One of the patient's arms is randomized to receive topical epigallocatechin gallate (Polyphenon E), the other arm to receive a placebo. Patients receive topical applications daily for 12 weeks, or until resolution of all actinic keratoses within the treatment field.

PROJECTED ACCRUAL: A minimum of 60 patients will be accrued for this study over 10 months.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. participants multiple sites of actinic keratosis identified by clinical examination and the histologic confirmation of one lesion (Grade 1-3 as defined previously in "Clinical Grading") are eligible.
  2. No history of invasive cancer within 5 years (though non-melanoma skin cancer, stage I cervical cancer, or chronic lymphocytic leukemia (CLL) stage 0 will not be reason to exclude a patient); no severe metabolic disorders or other life-threatening acute or chronic disease; no additional x-ray or chemotherapy anticipated.
  3. Not requiring use of topical medications in areas being studied.
  4. Subjects must meet the Southwest Oncology Group performance status criteria of 0 - 1 (0= fully active, able to carry on all pre-disease activities without restriction [Karnofsky scale 90 - 100]; 1 = restricted in physically strenuous activity, but ambulatory and able to carry out work of a light or sedentary nature, i.e. light housework or office work [Karnofsky scale 70 - 80]).
  5. Signed informed consent approved by the local Human Subjects Committee (Institutional Review Board).

Exclusion Criteria:

  1. Use of the following systemic or local therapies for the periods specified, prior to entry into the study:

    Within 2 weeks: topical medications, e.g. corticosteroids, alpha-hydroxyacids (glycolic acid, lactic acid) or retinoids (Retin-A) to the target lesions Within 4 weeks: systemic steroid therapy. Within 2 months: cryotherapy to the target lesions, laser resurfacing, chemical peels, topical application of 5-fluorouracil (5-FU) or masoprocol (Actinex) for treatment of actinic keratoses. Systemic treatment with chemotherapeutic agents, psoralens, immunotherapy, retinoids (Tegison, Accutane).

  2. Any medical condition which , in the opinion of the investigator, could preclude study participation
  3. Active infectious diseases such as tuberculosis (TB) or HIV that may affect the patient systemically and may also affect the immune system. Localized, minor infections such as sinusitis, uncomplicated urinary tract infection, otitis media, etc. will not be criteria for exclusion from the study.
  4. Use of any investigational drug in the previous 30 days.
  5. Any history of keloid formation.
  6. Pregnant or nursing patients.
  7. Participants who may be unreliable for the study, including those engaging in excessive alcohol intake or drug abuse, or participants who are unable to return for scheduled follow-up visits
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00005097

United States, California
Chao Family Comprehensive Cancer Center
Orange, California, United States, 92868
Sponsors and Collaborators
University of California, Irvine
National Cancer Institute (NCI)
Study Chair: Frank L. Meyskens, MD, FACP Chao Family Comprehensive Cancer Center
  More Information

Responsible Party: Chao Family Comprehensive Cancer Center, Cancer Center, University of California, Irvine Identifier: NCT00005097     History of Changes
Other Study ID Numbers: CDR0000067798
UCIRVINE-N01-CN-85182 ( Other Identifier: UC Irvine )
NCI-P00-0142 ( Registry Identifier: National Cancer Insitute )
UCI 98-31 ( Other Identifier: University of California, Irvine )
1998-420 ( Other Identifier: University of California, Irvine )
Study First Received: April 6, 2000
Last Updated: April 17, 2014

Keywords provided by Chao Family Comprehensive Cancer Center, University of California, Irvine:
squamous cell carcinoma of the skin

Additional relevant MeSH terms:
Keratosis, Actinic
Skin Neoplasms
Skin Diseases
Precancerous Conditions
Neoplasms by Site processed this record on September 21, 2017